<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2221</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>LOW MOLECULAR WEIGHT CHITOSAN AS A VEHICLE FOR SOLUBILIZATION AND AMORPHIZATION OF NON STEROID ANTI-INFLAMMATORY DRUG FOR A NEW GUAR GUM-BASED COLON DELIVERY FORMULATION&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname/><given-names/></name></contrib><contrib contrib-type="author"><name><surname>Nahla</surname><given-names>Barakat</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fars</surname><given-names>Alanazi</given-names></name></contrib></contrib-group><volume/><issue/><fpage>7</fpage><lpage>24</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>The solubilization and amorphization of the poorly water soluble nonsteroidal antiinflammatory drug, Etodolac (ETD) with a hydrophilic polymer, low molecular weight chitosan (CHT), have investigated. Phase solubility studies were carried out to obtain an insight on the nature of a possible interaction between ETD and CHT in&#13;
solution. Binary systems of varying drug polymer ratios were prepared using different techniques namely physical mixing, cogrinding and kneading. Drug__ampersandsignndash;polymer interactions were investigated in solid stateby differential scanning calorimetry, powder X-ray diffractometry and scanning electron microscopy. The results obtained indicated loss of drug crystallinity. Dissolution rate studies revealed that the drug dissolution was improved with increasing the polymer concentration in the mixture in the following order kneading__ampersandsigngt; co-grinding__ampersandsigngt; physical mixing __ampersandsigngt; pure drug. The prepared capsules containing the binary mixture prepared by&#13;
kneading in the drug-polymer ratio of 1:19 were coated with guar gum (a film coating material) and their dissolution rates were tested in comparison with commercial capsules present in the Egyptian market. A coating of 10 layers of guar gum prevented the release of etodolac in the acidic pH and permitted its release in colonic environment.&#13;
</p></abstract><kwd-group><kwd>Etodolac</kwd><kwd> Binary mixtures</kwd><kwd> Chitosan</kwd><kwd> Film coating</kwd><kwd> Guar gum.</kwd></kwd-group></article-meta></front></article>
